Advertisement

Management of Recurrent Lymph Nodes in Central and Lateral Neck in the Follow-Up of Differentiated Thyroid Carcinoma

  • Seyfettin Ilgan
Chapter

Abstract

Despite excellent overall prognosis, up to 40% of patients with papillary thyroid cancer (PTC) will have persistent or recurrent disease, mostly in lateral (53%) or central (28%) cervical lymph nodes. Local and regional recurrences continue to be treated by surgical excision with or without adjuvant radioiodine treatment, especially in potentially curable patients. Discovery of nonpalpable nodal recurrences in the central and lateral neck have been increased considerably with the evolving role of ultrasonography in the follow-up of patients with PTC. However, the management of impalpable or indolent locoregional recurrences of PTC continues to be more controversial. Despite arguments over survival benefit of reoperations, 19–73% remission rates have been reported based on Tg levels with compartment-oriented reoperations. The correct delineation of the disease preoperatively and the use of new techniques facilitating identification of recurrent laryngeal nerve and metastatic foci during surgery are essential parts of therapeutic success.

Keywords

Thyroid cancer Lymph node Metastases Radioguided surgery 

References

  1. 1.
    Ilgan S, Oztürk E, Yildiz R, Emer O, Ayan A, Görgülü S, et al. Combination of preoperative ultrasonographic mapping and radioguided occult lesion localization in patients with locally recurrent/persistent papillary thyroid carcinoma: a practical method for central compartment reoperations. Clin Nucl Med. 2010;35:847–52.  https://doi.org/10.1097/RLU.0b013e3181f48403.CrossRefPubMedGoogle Scholar
  2. 2.
    Amin MB, Edge SB, Greene FL, Compton CC, Gershenwald JE, Brookland RK, et al., editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.Google Scholar
  3. 3.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.  https://doi.org/10.1089/thy.2015.0020.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Sem Oncol. 1987;14:315–32.Google Scholar
  5. 5.
    Coburn M, Teates D, Wanebo HJ. Recurrent thyroid cancer: role of surgery versus radioactive iodine (I-131). Ann Surg. 1994;6:587–95.CrossRefGoogle Scholar
  6. 6.
    Noguchi M, Kumaki T, Taniya T, Segawa M, Nakano T, Ohta N, et al. Impact of neck dissection on survival in well-differentiated thyroid cancer: a multivariate analysis of 218 cases. Int Surg. 1990;75:220–4.PubMedGoogle Scholar
  7. 7.
    Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck. 1996;18:127–32.CrossRefGoogle Scholar
  8. 8.
    Travagli JP, Cailleux AF, Ricard M. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:2675–80.  https://doi.org/10.1210/jcem.83.8.5014.CrossRefPubMedGoogle Scholar
  9. 9.
    Bin Yousef HM, Alzahrani AS, Al Sobhi SS, Al SH, Chaudhari MA, Raef HM. Preoperative neck ultrasonographic mapping for recurrent/persistent papillary thyroid cancer. World J Surg. 2004;28:1110–4.  https://doi.org/10.1007/s00268-004-7636-5.CrossRefGoogle Scholar
  10. 10.
    Alzahrani AS, Raef H, Sultan A, Al Sobhi S, Ingemansson S, Ahmed M, et al. Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer. J Endocrinol Investig. 2002;25:526–31.CrossRefGoogle Scholar
  11. 11.
    Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937–41.CrossRefGoogle Scholar
  12. 12.
    Kim MK, Mandel SH, Baloch Z, Livolsi VA, Langer JE, Didonato L, et al. Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer. Arch Otolaryngol Head Neck Surg. 2004;130:1214–6.  https://doi.org/10.1001/archotol.130.10.1214.CrossRefPubMedGoogle Scholar
  13. 13.
    Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 1985;55:794–804.CrossRefGoogle Scholar
  14. 14.
    Wilson DB, Staren ED, Prinz RA. Thyroid reoperations: indications and risks. Am Surg. 1998;64:674–8.PubMedGoogle Scholar
  15. 15.
    Karwowski JK, Jeffrey RB, McDougall IR, Weigel RJ. Intraoperative ultrasonography improves identification of recurrent thyroid cancer. Surgery. 2002;132:924–9.  https://doi.org/10.1067/msy.2002.128478.CrossRefPubMedGoogle Scholar
  16. 16.
    McCoy KL, Yim JH, Tublin ME, Burmeister LA, Ogilvie JB, Carty SE. Same-day ultrasound guidance in reoperation for locally recurrent papillary thyroid cancer. Surgery. 2007;142:965–72.  https://doi.org/10.1016/j.surg.2007.09.021.CrossRefPubMedGoogle Scholar
  17. 17.
    Priven I, Schwartz A, Yeh H. Ultrasonographic localization and marking of a small recurrent thyroid papillary carcinoma. Thyroid. 2003;13:663.  https://doi.org/10.1089/105072503322240022.CrossRefPubMedGoogle Scholar
  18. 18.
    Zimmerman P, DaSilva M, Izquierdo R, Cico L, Kort K, Numan P. Intraoperative needle localization during neck reexploration. Am J Surg. 2004;188:92–3.  https://doi.org/10.1016/j.amjsurg.2002.11.037.CrossRefPubMedGoogle Scholar
  19. 19.
    Triponez F, Poder L, Zarnegar R, Goldstein R, Roayaie K, Feldstein V, et al. Hook needle-guided excision of recurrent differentiated thyroid cancer in previously operated neck compartments: a safe technique for small, nonpalpable recurrent disease. J Clin Endocrinol Metab. 2006;91:4943–7.  https://doi.org/10.1210/jc.2006-0386.CrossRefPubMedGoogle Scholar
  20. 20.
    Sippel RS, Elaraj DM, Poder L, Duh QY, Kebebew E, Clark OH. Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection. World J Surg. 2009;33:434–9.CrossRefGoogle Scholar
  21. 21.
    Salvatore M, Ruffini V, Reale F. Radio-guided surgery for lymph node recurrences of differentiated thyroid cancer. World J Surg. 2003;27:770–5.CrossRefGoogle Scholar
  22. 22.
    Gulec SA, Eckert M, Woltering EA. Gamma probe-guided lymph node dissection (gamma picking) in differentiated thyroid carcinoma. Clin Nucl Med. 2002;27:859–61.CrossRefGoogle Scholar
  23. 23.
    Agrawal A, Hall NC, Ringel MD, Povoski SP, Martin EW Jr. Combined use of perioperative TSH-stimulated (18) F-FDG PET/CT imaging and gamma probe radioguided surgery to localize and verify resection of iodine scan-negative recurrent thyroid carcinoma. Laryngoscope. 2008;118:2190–4.  https://doi.org/10.1097/MLG.0b013e3181845738.CrossRefPubMedGoogle Scholar
  24. 24.
    Rubello D, Salvatori M, Casara D, Piotto A, Toniato A, Gross MD, et al. 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer. Eur J Surg Oncol. 2007;33:902–6.  https://doi.org/10.1016/j.ejso.2006.12.016.CrossRefPubMedGoogle Scholar
  25. 25.
    Nadeem R, Chagla LS, Harris O, Desmond S, Thind R, Titterrell C, et al. Occult breast lesions: a comparison between radioguided occult lesion localization (ROLL) vs. wire-guided lumpectomy (WGL). Breast. 2005;14:283–9.  https://doi.org/10.1016/j.breast.2005.04.002.CrossRefPubMedGoogle Scholar
  26. 26.
    Tukenmez M, Erbil Y, Barbaros U, Dural C, Salmaslioglu A, Aksoy D, et al. Radio-guided nonpalpable metastatic lymph node localization in patients with recurrent thyroid cancer. J Surg Oncol. 2007;96:534–8.  https://doi.org/10.1002/jso.20873.CrossRefPubMedGoogle Scholar
  27. 27.
    Park JH, Lee YS, Kim BW, Chang HS, Park CS. Skip lateral neck node metastases in papillary thyroid carcinoma. World J Surg. 2012;36:743–7.  https://doi.org/10.1007/s00268-012-1476-5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Seyfettin Ilgan
    • 1
  1. 1.Department of Nuclear MedicineGüven HospitalAnkaraTurkey

Personalised recommendations